Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2024-02-29 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended December 31, 2023. It is a certification letter rather than the interim report itself, and it explicitly states it is a Venture Issuer Basic Certificate under NI 52-109. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3030 characters), consistent with a certification letter rather than a full report.
2024-02-29 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim Management’s Discussion and Analysis – Quarterly Highlights for the three and six months ended December 31, 2023' and is dated February 25, 2024. It explicitly states it is an Interim MD&A prepared in compliance with Form 51-102F1 and National Instrument 51-102, which are Canadian continuous disclosure obligations. The content includes management's discussion of business operations, liquidity, capital resources, forward-looking statements, and risk factors for the interim period ending December 31, 2023. It references unaudited condensed interim consolidated financial statements prepared under IFRS and International Standard 34 for interim financial reporting. The document length is substantial (15,000 characters), indicating it is the actual report, not just an announcement. This matches the definition of an Interim / Quarterly Report (IR), which must contain substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR with high confidence.
2024-02-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three and six months ended December 31, 2023 and 2022. It contains detailed unaudited financial statements including statements of financial position, comprehensive loss, cash flows, and changes in shareholders' equity. The notes indicate compliance with IFRS and reference IAS 34, which governs interim financial reporting. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and format clearly identify it as a comprehensive financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2024-02-29 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Form 51-102F3 Material Change Report' and details a material change event involving the closing of a financing offering by Numinus Wellness Inc. It includes specifics about the offering size, price, underwriters, use of proceeds, and insider participation. The form number 51-102F3 is a regulatory filing used in Canadian securities regulation to report material changes. The content focuses on a financing event and is not a full financial report, audit, or earnings release. It is not a report publication announcement since it contains substantive details of the material change itself. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2024-02-26 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, purchaser information, compensation paid in connection with the distribution, and related regulatory compliance data. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report type but a specific regulatory disclosure about securities distribution. The document is comprehensive and contains substantive data about the distribution event, fitting the category of a regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-02-23 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private placement offering of securities by Revive Therapeutics Ltd. It details the terms of the offering, use of proceeds, and regulatory approvals required. There are no financial statements or detailed financial performance data included. The document is focused on capital raising activity and financing terms, which aligns with a Capital/Financing Update. It is not an annual or interim report, earnings release, or any other report type. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2024-01-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.